Want to see CYTK full AI Analyst Report?
CYTK Stock Chart & Stats
$79.20
$0.81(1.01%)
At close: 4:00 PM EDT
$79.20
$0.81(1.01%)
Day’s Range― - ―
52-Week Range$54.30 - $88.31
Previous CloseN/A
Volume899.92K
Average Volume (3M)2.05M
Market Cap
$8.71B
Enterprise Value$11.35B
Total Cash (Recent Filing)$1.17B
Total Debt (Recent Filing)$1.27B
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Oct 29, 2026EPS Estimate
-1.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.21
Shares Outstanding139,023,420
10 Day Avg. Volume2,072,727
30 Day Avg. Volume2,053,889
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)-11.56
Price to Sales (P/S)86.62
P/FCF Ratio-14.26
Enterprise Value/Market Cap1.30
Enterprise Value/Revenue160.01
Enterprise Value/Gross Profit188.30
Enterprise Value/Ebitda-13.82
Forecast
1Y Price Target
$110.40Price Target Upside39.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)-6.03
Revenue Forecast (FY)$153.21M
Bulls Say, Bears Say
Bulls Say
MYQORZO Launch TractionRapid growth in dispensed patients, prescriptions, prescriber reach, and product revenue provides evidence of early commercial adoption. Continued expansion could establish MYQORZO as a recurring product franchise and gradually diversify revenue beyond collaborations and milestone payments.
Regulatory ExpansionThe Canadian authorization expands MYQORZO’s approved geographic and patient-market opportunity, supporting future commercial reach beyond the initial U.S. launch. It also validates regulatory progress for the company’s muscle-function treatment platform and can support additional regional commercialization.
Positive Aficamten Pivotal DataPositive pivotal results strengthen the case for expanding aficamten into symptomatic non-obstructive HCM, potentially broadening the addressable market beyond the current indication. A supplemental filing planned for Q4 2026 creates a defined regulatory path for this pipeline opportunity.
Bears Say
Heavy Cash BurnThe scale of operating and free-cash-flow losses means commercialization and clinical development require substantial external funding. Persistent cash consumption can reduce financial flexibility over the next several quarters and increase dependence on additional capital or successful product launches.
Pressured Capital StructureNegative equity combined with substantial debt indicates a weaker capital structure and greater reliance on debt or capital markets. This can constrain strategic flexibility, raise financing sensitivity, and leave less balance-sheet capacity to absorb setbacks in development or commercialization.
High Costs And Uneven RevenueRevenue remains vulnerable to the timing of licensing and milestone payments, while launch and development spending is rising sharply. The mismatch between uneven revenue and elevated expenses prolongs losses and makes near-term profitability dependent on product uptake and regulatory execution.
Cytokinetics News
CYTK FAQ
What was Cytokinetics’s price range in the past 12 months?
Cytokinetics lowest stock price was $54.30 and its highest was $88.31 in the past 12 months.
What is Cytokinetics’s market cap?
Cytokinetics’s market cap is $8.71B.
When is Cytokinetics’s upcoming earnings report date?
Cytokinetics’s upcoming earnings report date is Oct 29, 2026 which is in 8 days.
How were Cytokinetics’s earnings last quarter?
Cytokinetics released its earnings results on Aug 06, 2026. The company reported -$1.5 earnings per share for the quarter, beating the consensus estimate of -$1.628 by $0.128.
Is Cytokinetics overvalued?
According to Wall Street analysts Cytokinetics’s price is currently Undervalued.
Does Cytokinetics pay dividends?
Cytokinetics does not currently pay dividends.
What is Cytokinetics’s EPS estimate?
Cytokinetics’s EPS estimate is -1.44.
How many shares outstanding does Cytokinetics have?
Cytokinetics has 139,023,420 shares outstanding.
What happened to Cytokinetics’s price movement after its last earnings report?
Cytokinetics reported an EPS of -$1.5 in its last earnings report, beating expectations of -$1.628. Following the earnings report the stock price went down -5.665%.
Which hedge fund is a major shareholder of Cytokinetics?
Currently, no hedge funds are holding shares in CYTK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cytokinetics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$110.40 (39.39% Upside)
$110.40 (39.39% Upside)
Blogger Sentiment
Neutral
CYTK Sentiment 50%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 596.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $13.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.75%
12-Months-Change
Fundamentals
Return on Equity
163.98%
Trailing 12-Months
Asset Growth
57.02%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cytokinetics
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
CYTK Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial operational and clinical progress: strong early commercial momentum for MYQORZO (rapidly growing prescriptions, rising awareness, >700 prescribers and >1,500 dispensed patients), pivotal ACACIA-HCM positive results with planned sNDA submission, successful European regulatory steps and a $760M financing that boosted cash to ~$1.7B. These strategic and scientific achievements were balanced against near-term financial headwinds including a YOY revenue decline driven by absence of milestone revenue, a wider GAAP net loss ($198.8M), sharply higher SG&A tied to launch costs and upwardly revised 2026 expense guidance. Overall, the operational wins, pivotal data and strong cash position indicate a constructive outlook for growth and future approvals, though investors should expect continued elevated spending as the company scales commercialization and pursues regulatory filings.View all CYTK earnings summariesCYTK Stock 12 Month Forecast
Average Price Target
$110.40
▲(39.39% Upside)
Technical Analysis
Sarepta Therapeutics
―
PTC Therapeutics
―
Scholar Rock Holding
―
Dyne Therapeutics
―
Edgewise Therapeutics
―
Ownership Overview
0.63% Insiders
34.89% Mutual Funds
0.40% Other Institutional Investors
38.09% Public Companies and
Individual Investors